human
genom
encod
proteas
molecular
scissor
play
import
role
essenti
physiolog
process
digest
protein
food
degrad
misfold
unwant
protein
regul
traffick
activ
numer
cellular
factor
proteolyt
cleavag
certainli
one
import
modif
gener
plethora
bioactiv
protein
peptid
key
role
cell
prolifer
immun
inflamm
surprisingli
mutat
proteas
andor
aberr
proteas
activ
associ
numer
patholog
process
includ
cancer
cardiovascular
disord
autoimmun
intriguingli
also
mani
viral
pathogen
exploit
cellular
proteas
proteolyt
process
matur
protein
similarli
activ
bacteri
toxin
frequent
requir
cleavag
proteas
infect
intox
host
recent
year
modul
proteas
activ
therefor
emerg
potenti
therapeut
approach
varieti
infecti
noninfecti
diseas
one
particularli
promis
target
therapeut
intervent
cellular
proteas
furin
proteas
like
cleav
activ
mammalian
viral
bacteri
among
viral
envelop
glycoprotein
bacteri
toxin
well
cellular
factor
promot
tumor
develop
growth
hyperactiv
figur
review
summaris
current
knowledg
protein
process
health
diseas
focu
role
furin
viral
protein
process
furthermor
describ
cellular
mechan
regul
furin
activ
transcript
level
final
present
approach
aim
modul
furin
activ
therapeut
purpos
discuss
suitabl
clinic
applic
furin
member
evolutionarili
ancient
famili
proprotein
convertas
similar
bacteri
subtilisin
yeast
kexin
proteas
coin
abbrevi
pcsk
proprotein
convertas
subtilisinkexin
type
human
encod
nine
member
proteas
famili
repres
furin
tabl
pcsk
well
known
abil
activ
cellular
protein
proteolyt
convers
inact
precursor
protein
bioactiv
molecul
alreadi
describ
howev
took
year
furin
identifi
first
mammalian
proprotein
date
cellular
substrat
pcsk
describ
includ
hormon
receptor
growth
factor
adhes
molecul
although
pcsk
frequent
coexpress
cell
may
cleav
substrat
complet
redund
inactiv
individu
pcsk
result
specif
phenotyp
cleav
substrat
basic
residu
typic
recognit
motif
tabl
contrast
cleav
nonbas
residu
best
known
regul
cholesterol
lipid
metabol
activ
sterol
regulatori
protein
srebp
transcript
like
also
play
key
role
cholesterol
metabol
regul
lipoprotein
ldl
particl
level
blood
howev
effect
involv
proteolyt
cleavag
specif
substrat
mediat
direct
bind
ldl
two
inhibitor
treatment
hypercholesterolaemia
also
prime
exampl
proteas
success
target
prototyp
member
pcsk
famili
sinc
cleav
basic
amino
acid
motif
also
term
pace
pair
basic
amino
acid
cleav
enzym
furin
express
fur
fe
upstream
region
gene
chromosom
although
furin
ubiquit
express
mrna
protein
level
vari
depend
cell
type
tissu
high
level
found
salivari
gland
liver
bone
marrow
wherea
muscl
cell
express
rel
low
amount
three
promot
harbour
altern
transcript
start
site
describ
figur
howev
respect
transcript
differ
first
untransl
exon
therefor
predict
express
promot
resembl
constitut
express
housekeep
gene
promot
bind
transcript
factor
upon
cytokin
line
pma
induc
furin
upon
translat
mrna
furin
enter
secretori
pathway
inact
proenzym
integr
er
membran
via
transmembran
domain
figur
like
type
transmembran
protein
harbour
short
signal
peptid
cleav
cotransl
similar
proprotein
convertas
furin
contain
inhibitori
acid
propeptid
whose
chaperon
function
requir
correct
fold
catalyt
transit
furin
er
network
tgn
inhibitori
propeptid
remov
autoproteolyt
process
furin
gain
enzymat
time
oligosaccharid
ad
trim
although
furin
accumul
tgn
transport
cell
surfac
back
via
endosom
final
furin
also
shed
releas
extracellular
space
upon
proteolyt
separ
catalyt
domain
c
whether
cleavag
step
mediat
furin
anoth
proteas
remain
presenc
furin
tgn
endosom
compart
cell
surfac
extracellular
space
may
explain
abil
process
larg
varieti
extracellular
substrat
canon
furin
cleavag
site
frequent
describ
howev
variat
motif
may
also
recognis
stretch
amino
acid
surround
cleavag
site
well
modif
determin
interact
furin
bind
bioinformat
analys
function
studi
uncov
furin
cleavag
site
mammalian
protein
compris
growth
factor
cytokin
eg
ngf
hormon
eg
pth
trh
ghrh
adhes
molecul
eg
integrin
vitronectin
collagen
metalloproteinas
coagul
factor
receptor
membran
channel
target
factor
activ
upon
cleavag
furin
also
exert
inactiv
cleavag
step
exampl
furin
paralogu
endotheli
lipas
inactiv
physiolog
import
furin
reflect
furin
mice
die
embryon
day
cardial
ventral
closur
defect
hemodynam
similarli
endotheli
furin
result
cardiac
malform
death
shortli
even
mutat
cleavag
site
singl
furin
target
protein
may
detriment
effect
result
genet
disord
haemophilia
b
hypohidrot
ectoderm
pleiotrop
effect
variat
furin
express
level
andor
enzymat
activ
may
detriment
effect
promot
pathogenesi
varieti
disord
includ
rheumatoid
arthriti
amyloid
dementia
furin
term
master
switch
tumor
growth
progress
aberr
express
activ
promot
format
progress
variou
malign
includ
colon
carcinoma
rhabdomyosarcoma
head
neck
cancer
lung
skin
brain
case
furin
level
posit
correl
aggress
increas
furin
express
propos
prognost
marker
advanc
oncogen
prometastat
activ
furin
ascrib
abil
activ
protein
promot
cell
prolifer
angiogenesi
migrat
tissu
invas
exampl
furin
cleav
activ
growth
factor
igf
pdgf
ngf
enhanc
cell
prolifer
consequ
tumor
growth
similarli
angiogen
lymphangiogen
factor
may
hyperactiv
promot
vascularis
growth
solid
notabl
furin
express
induc
hypoxia
three
fur
promot
harbour
bind
site
thu
vascularis
may
preferenti
occur
otherwis
hypox
tumor
interestingli
hypoxia
also
result
subcellular
relocalis
furin
cell
surfac
may
enhanc
process
growth
factor
extracellular
tumorigen
precursor
besid
effect
tumor
growth
furin
also
promot
migrat
extravas
malign
cell
process
adhes
molecul
mediat
interact
cleavag
integrin
may
particularli
relev
mediat
adhes
cell
extracellular
matrix
also
act
signal
transduc
regul
cell
growth
divis
addit
furin
activ
matrix
metalloproteinas
eg
facilit
metastasi
degrad
compon
extracellular
final
increas
furin
activ
may
also
promot
cancer
develop
suppress
protect
antitumor
mechan
exampl
increas
activ
reduc
immun
surveil
promot
develop
suppress
treg
cell
inhibit
effector
key
role
furin
immun
highlight
furin
mice
harbour
inher
effector
cell
secret
reduc
level
activ
notabl
posit
feedback
loop
enhanc
oncogen
potenti
furin
exampl
furin
substrat
increas
furin
mrna
express
also
enhanc
proteolyt
activ
unknown
similarli
furin
enhanc
secret
turn
activ
fur
mutual
enhanc
seem
particularli
import
given
key
role
tumor
develop
one
hand
releas
may
benefici
effect
boost
tumorlyt
activ
natur
killer
cell
cytotox
lymphocyt
furthermor
may
act
antiangiogen
factor
directli
inhibit
tumor
cell
prolifer
induc
express
tumor
suppressor
hand
howev
recent
evid
suggest
may
also
exert
effect
exampl
select
immun
evas
phenotyp
promot
immunosuppress
tumor
intriguingli
studi
laryng
cancer
patient
suggest
feedback
loop
may
boost
iatrogen
sinc
radiotherapi
increas
furin
express
summari
aberr
furin
activ
promot
sever
step
cancer
develop
includ
cell
prolifer
vascularis
metastasi
antitumor
immun
howev
rel
contribut
individu
furin
substrat
tumor
progress
role
proprotein
convertas
remain
larg
unclear
furin
may
promot
diseas
upon
aberr
express
also
activ
varieti
protein
one
exampl
cleavag
unwant
protein
proteolyt
activ
bacteri
toxin
particularli
group
ab
toxin
compris
sever
furin
substrat
exotoxin
secret
bacteria
exert
effect
cytoplasm
target
cell
usual
consist
enzymat
activ
subunit
b
subunit
mediat
membran
bind
transloc
exert
toxic
effect
subunit
separ
b
subunit
proteolyt
case
diphtheria
toxin
pseudomona
exotoxin
furin
cleav
target
sequenc
cleavag
like
occur
endosom
subunit
transloc
nucleu
inhibit
protein
synthesi
inhibit
elong
factor
line
import
role
furin
bacteri
virul
toxic
highest
optim
furin
cleavag
site
similarli
furin
cleav
shiga
toxin
express
certain
shigella
spp
escherichia
coli
strain
enhanc
abil
halt
protein
synthesi
although
furin
target
sequenc
conserv
among
toxin
mutat
analys
suggest
cleavag
augment
toxin
activ
anoth
exampl
anthrax
toxin
exotoxin
consist
receptor
bind
protect
antigen
pa
enzymat
activ
compon
oedema
factor
ef
lethal
factor
lf
upon
bind
receptor
pa
cleav
furin
cell
surfac
cleavag
step
trigger
oligomeris
pa
prepor
bind
ef
lf
subsequ
toxin
complex
endocytos
pa
form
channel
allow
transloc
ef
lf
although
pa
activ
differ
proprotein
convertas
famili
member
furin
seem
major
proteas
activ
anthrax
exampl
illustr
sever
bacteri
pathogen
exploit
furin
relat
convertas
activ
exotoxin
strictli
speak
howev
toxin
produc
bacteria
eg
diphtheria
toxin
shiga
toxin
repres
viral
gene
product
encod
case
term
viral
exotoxin
may
appropri
strongli
suggest
toxin
activ
confer
select
advantag
bacterium
phage
exampl
induct
cell
death
toxin
may
promot
tissu
invas
increas
transmiss
rate
eg
caus
diarrhoea
suppress
cellular
immun
respons
without
proteolyt
activ
exotoxin
diseas
dysenteri
diphtheria
would
occur
retrovir
glycoprotein
trimer
human
immunodefici
rou
sarcoma
murin
leukaemia
virus
proteolyt
process
activ
produc
cell
figur
left
panel
case
precursor
viral
envelop
protein
env
cleav
remain
associ
noncoval
interact
cleavag
occur
intracellular
compart
assembl
virion
plasma
membran
notabl
proteolyt
process
env
depend
correct
glycosyl
aberr
carbohydr
side
chain
may
result
subcellular
mistraffick
sequestr
like
take
advantag
redund
sever
proprotein
convertas
recognis
polybas
cleavag
motif
env
furin
shown
cleav
cell
albeit
differ
notabl
vitro
cleavag
experi
use
recombin
proteas
alway
reflect
cleavag
effici
transfect
cell
rel
contribut
individu
pcsk
matur
vivo
remain
interestingli
env
harbour
second
polybas
cleavag
site
eight
amino
acid
residu
upstream
major
one
although
cleavag
site
result
fusiogen
env
speci
molecul
cleav
posit
least
case
clone
case
escap
intracellular
cleavag
may
incorpor
unprocess
precursor
bud
virion
whether
env
molecul
may
process
extracellularli
shed
furin
unknown
context
noteworthi
plasmin
shown
convert
extracellular
howev
remain
determin
whether
cleavag
result
fulli
infecti
particl
influenza
viru
hemagglutinin
ha
cleav
prime
varieti
cellular
proteas
even
bacteri
proteas
may
promot
influenza
viru
spread
cleav
subunit
remain
link
via
disulphid
bond
form
trimer
structur
bind
sialic
acid
receptor
viral
target
cell
harbour
fusion
peptid
mediat
fusion
viral
cellular
endosom
membran
ha
cleavag
occur
within
produc
cell
upon
releas
virion
infect
cell
directli
prior
entri
new
target
gener
rule
hemagglutinin
mammalian
low
pathogen
avian
influenza
virus
cleav
furin
usual
harbour
dibas
cleavag
site
instead
depend
proteas
transmembran
proteas
serin
member
human
airway
proteas
hat
express
proteas
larg
restrict
respiratori
gastrointestin
tract
contrast
hemagglutinin
larg
number
highli
pathogen
avian
influenza
virus
hpaiv
cleav
furin
present
mani
cell
acquir
polybas
cleavag
site
upon
insert
addit
lysin
andor
arginin
residu
duplic
lysin
arginin
residu
ha
facilit
polymeras
slippag
amino
acid
encod
instead
prototyp
motif
hpaiv
harbour
suboptim
cleavag
motif
proteolyt
cleavag
site
effici
addit
posit
charg
amino
acid
upstream
cleavag
motif
present
attach
site
mask
oligosaccharid
chain
notabl
subset
lowli
pathogen
avian
influenza
viru
strain
also
harbour
site
cleav
proteas
hat
also
howev
cleavag
effici
presenc
high
amount
furin
upon
mutat
glycosyl
site
thu
abil
exploit
furin
effici
ha
cleavag
associ
increas
pathogen
determin
presenc
furin
consensu
target
site
also
adjac
residu
absenc
mask
oligosaccharid
chain
furin
cleav
glycoprotein
gp
marburg
viru
marv
five
ebolaviru
speci
larg
subunit
mediat
receptor
bind
small
part
contain
fusion
marv
human
pathogen
ebolaviru
speci
harbour
canon
furin
cleavag
site
contrast
gp
close
relat
reston
viru
caus
asymptomat
infect
human
process
less
effici
furin
carri
suboptim
cleavag
site
surprisingli
howev
uncleav
gp
mutant
highli
pathogen
ebola
viru
ebov
abl
mediat
infect
cleavag
requir
replic
cell
furthermor
ebov
mutant
lack
furin
cleavag
site
replic
effici
nonhuman
primat
show
differ
diseas
progress
lethal
compar
thu
high
conserv
furin
cleavag
site
among
differ
ebolaviru
speci
surpris
remain
determin
whether
gp
process
play
role
natur
reservoir
host
notabl
ebov
gp
gene
harbour
rna
edit
site
sequenc
may
express
gp
also
solubl
form
glycoprotein
lack
transmembran
intriguingli
harbour
anoth
furin
recognit
site
cleav
matur
sgp
short
peptid
ultim
releas
infect
although
produc
higher
amount
gp
role
viral
replic
debat
among
other
sgp
suggest
serv
decoy
antigen
act
structur
substitut
induc
apoptosi
uninfect
flaviviru
rna
translat
singl
larg
polyprotein
cleav
cellular
viral
proteas
structur
nonstructur
protein
viru
structur
protein
compris
envelop
protein
prm
e
incorpor
prme
heterodim
bud
prm
act
chaperon
facilit
correct
fold
e
mani
flavivirus
bud
lumen
er
enter
secretori
acid
milieu
network
tgn
furin
cleavag
site
expos
prm
cleav
matur
pr
thu
cleavag
viral
glycoprotein
occur
incorpor
newli
form
virion
figur
right
panel
contrast
virus
hiv
whose
envelop
protein
cleav
assembl
pr
peptid
remain
associ
e
protein
virion
releas
cell
therebi
prevent
prematur
unintend
fusion
membran
produc
prm
cleavag
essenti
replic
flavivirus
enceph
dengu
case
prm
molecul
escap
furin
process
produc
cell
result
releas
immatur
partial
matur
viral
particl
partial
matur
virion
still
infecti
sinc
low
amount
matur
suffici
mediat
fusion
target
cell
furthermor
uncleav
prm
may
particip
virion
attach
target
cell
cleav
furin
entri
process
acid
milieu
figur
left
panel
rel
contribut
prm
process
viral
entri
new
target
cell
howev
remain
determin
ratio
matur
immatur
prm
depend
varieti
factor
includ
produc
cell
type
flaviviru
speci
exampl
dengu
virus
known
releas
high
amount
immatur
partial
matur
virus
like
conserv
acid
residu
within
furin
recognit
tabl
importantli
content
prm
viral
particl
also
affect
antibodi
recognit
consequ
enhanc
dengu
viru
thu
protein
process
may
markedli
affect
outcom
infect
furin
play
key
role
activ
envelop
glycoprotein
varieti
virus
activ
also
exploit
cleavag
viral
protein
one
exampl
cleavag
protein
togeth
major
capsid
protein
minor
capsid
protein
build
viral
capsid
furin
cleavag
site
locat
close
n
terminu
highli
conserv
among
differ
human
papillomaviru
hpv
cleavag
requir
viru
assembl
releas
essenti
infect
new
target
cell
exampl
lovo
cho
cell
lack
furin
express
complet
resist
infect
pseudovirus
one
hpv
type
caus
cervic
cancer
contrast
flaviviru
prm
cleav
egress
entri
papillomaviru
seem
exclus
cleav
target
model
propos
attach
papillomavirus
heparan
sulphat
proteoglycan
induc
conform
chang
expos
polybas
cleavag
upon
proteolyt
process
may
engag
secondari
cellular
receptor
mediat
figur
right
panel
furthermor
interact
cleav
unknown
intracellular
receptor
may
requir
escap
endosom
compart
abil
escort
viral
dna
illustr
also
nonenvelop
virus
evolv
abil
exploit
furin
relat
pcsk
purpos
anoth
nonenvelop
protein
cleav
furin
extern
core
antigen
hbeag
hepat
b
viru
hbv
cleav
hbeag
secret
infect
cell
exert
immunosuppress
suggest
act
tolerogen
prevent
kill
infect
hepatocyt
cytotox
contrast
uncleav
hbeag
may
opposit
effect
transport
plasma
membran
trigger
antivir
immun
thu
cleavag
hbeag
may
affect
outcom
infect
intriguingli
han
chines
frequent
harbour
singl
nucleotid
polymorph
promot
fur
gene
associ
increas
risk
develop
persist
hbv
infect
detect
amount
hbeag
polymorph
increas
bind
effici
hepat
transcript
factor
therebi
like
increas
furin
whether
observ
increas
hbv
persist
result
increas
hbeag
process
andor
effect
furin
remain
determin
viral
pathogen
host
continu
arm
although
virus
evolv
sophist
strategi
exploit
metabol
protein
synthesi
traffick
pathway
infect
cell
host
defenceless
besid
innat
adapt
immun
respons
directli
target
compon
viru
infect
cell
may
also
restrict
viral
spread
limit
avail
cellular
factor
critic
viral
replic
viru
depend
factor
exampl
host
protein
restrict
replic
sever
viral
pathogen
deplet
cellular
dntp
furthermor
target
cellular
transcript
factor
suppress
viral
gene
intriguingli
accumul
evid
suggest
inhibit
viru
depend
factor
furin
repres
anoth
effici
broadli
activ
mechan
antivir
immun
aert
colleagu
found
receptor
receptor
interfer
express
furin
process
human
metapneumoviru
f
experi
reveal
harbour
motif
mediat
interact
sever
line
solubl
cleav
abrog
abil
induc
calcium
signal
upon
cleavag
plasma
membran
surprisingli
howev
pcsk
furin
fail
cleav
posit
instead
furin
trap
network
prevent
anterograd
transport
cell
surfac
figur
time
also
block
proteolyt
activ
furin
inhibit
exampl
matur
env
inhibitori
activ
share
paralogu
effici
cleav
notabl
express
induc
proinflammatori
environ
brain
infect
individu
suffer
neurocognit
disord
hand
thu
furin
inhibit
may
repres
mechan
innat
immun
limit
spread
potenti
addit
viral
pathogen
similar
inhibitori
activ
recent
describ
two
gtpase
term
protein
initi
describ
screen
novel
restrict
factor
hiv
shown
interfer
matur
retrovir
env
experi
reveal
antivir
activ
share
paralogu
protein
reduc
proteolyt
activ
amount
furin
result
cleavag
env
precursor
matur
reduc
newli
form
virion
poorli
infecti
figur
sinc
mani
viral
pathogen
reli
furin
relat
pcsk
matur
glyco
protein
exert
broad
antivir
activ
inhibit
replic
highli
pathogen
avian
influenza
measl
zika
virus
contrast
decreas
infect
virion
carri
glycoprotein
vesicular
stomat
viru
requir
proteolyt
activ
step
notabl
inhibit
furin
infect
cell
come
cost
sinc
process
matrix
metalloproteinas
cellular
substrat
also
reduc
presenc
increas
futur
experi
reveal
whether
inhibit
furin
activ
may
also
prevent
develop
prolifer
certain
cancer
remark
increas
express
associ
favor
outcom
patient
suffer
melanoma
breast
thu
better
understand
cellular
mechan
regul
furin
activ
help
understand
pathogenesi
infecti
diseas
cancer
may
uncov
novel
target
therapeut
intervent
key
role
furin
pathogenesi
cancer
infecti
diseas
suitabl
therapeut
target
rais
signific
interest
sever
year
mani
laboratori
explor
possibl
limit
tumor
growth
viral
replic
bacteri
intox
reduc
amount
proteolyt
activ
furin
initi
studi
focus
peptid
protein
bind
activ
site
furin
inhibit
substrat
bind
competit
manner
exampl
variant
natur
occur
serin
proteas
inhibitor
antitrypsin
modifi
harbour
consensu
furin
cleavag
site
variant
term
antitrypsin
portland
inhibit
furin
shown
prevent
process
env
measl
viru
f
similarli
peptid
deriv
cleavag
site
influenza
viru
hemagglutinin
polyarginin
compet
natur
furin
even
exogen
addit
autoinhibitori
propeptid
furin
shown
reduc
enzymat
activ
limit
exampl
activ
breast
cancer
howev
therapeut
potenti
propeptid
never
evalu
vivo
inhibitori
effect
like
limit
known
dissoci
furin
tgn
sever
approach
includ
incorpor
instead
acid
appli
increas
stabil
henc
efficaci
furin
inhibitor
exampl
one
first
furin
inhibitor
exhibit
good
stabil
prevent
cytotox
effect
pseudomona
exotoxin
vitro
similarli
topic
applic
shown
reduc
corneal
damag
mice
infect
pseudomona
interestingli
also
show
direct
bactericid
activ
probabl
polycation
besid
acid
incorpor
amino
acid
analog
decarboxyl
arginin
mimet
amba
use
increas
stabil
furin
furthermor
addit
chloromethyl
keton
cmk
moieti
c
terminu
polybas
cleavag
motif
proven
use
result
alkyl
activ
site
furin
irrevers
block
enzymat
nevertheless
cytotox
inhibitor
instabl
cmk
moieti
may
limit
use
topic
applic
treatment
hpv
skin
final
elucid
crystal
structur
furin
enabl
target
model
nonpeptid
inhibitor
compound
upon
addit
guanidin
residu
streptamin
deriv
mimic
cation
furin
cleavag
site
inhibit
enzymat
activ
nanomolar
rang
dahm
colleagu
describ
interest
exampl
inhibitor
two
molecul
inhibitor
form
complex
first
inhibitor
molecul
directli
interfer
conform
catalyt
triad
second
molecul
bind
adjac
planar
peptid
stretch
besid
stabil
subcellular
localis
furin
inhibitor
key
determin
efficaci
vivo
notabl
optim
localis
inhibitor
strongli
depend
process
event
target
therapeut
intervent
inhibit
activ
anthrax
toxin
exampl
inhibitor
need
enter
cell
furin
cleav
toxin
precursor
cell
surfac
contrast
penetr
inhibitor
cell
essenti
prevent
matur
env
viral
glycoprotein
cleav
intracellularli
inhibitor
eg
peptid
effici
enter
cell
other
modifi
increas
intracellular
avail
exampl
addit
decanoyl
moieti
cmk
inhibitor
increas
abil
penetr
streptamin
deriv
may
particularli
promis
target
therapi
posit
guanidyl
substitu
determin
localis
inhibitor
distinct
subcellular
compart
endosom
golgi
mani
inhibitor
describ
potent
reduc
furin
activ
vitro
vivo
also
inhibit
proprotein
convertas
recognis
similar
polybas
cleavag
site
limit
inher
competit
inhibitor
aim
mimick
target
sequenc
furin
may
overcom
alloster
inhibitor
bind
motif
outsid
activ
site
one
exampl
nanobodi
bind
furin
therebi
block
access
larger
substrat
activ
site
notabl
specif
bind
furin
recognis
instead
target
furin
protein
level
therapeut
approach
may
also
aim
target
rna
exampl
endogen
degrad
furin
mrna
andor
roquin
could
modul
interfer
express
thu
proteolyt
activ
amount
furin
howev
modul
roquin
like
effect
endoribonucleas
also
degrad
addit
mrna
select
approach
silenc
furin
via
shrna
fact
suppress
furin
express
current
clinic
advanc
therapi
target
proteas
phase
iii
clinic
trial
patient
suffer
metastat
ewe
sarcoma
famili
tumor
esft
treat
immunotherapi
involv
silenc
furin
simultan
overexpress
specif
tumor
cell
extracorpor
transfect
reintroduc
furin
augment
fang
cancer
vaccin
also
known
vigil
boost
antitumor
respons
dendrit
cell
cell
furin
prevent
proteolyt
activ
may
otherwis
revert
benefici
effect
phase
ii
clinic
trial
autolog
fangvigil
vaccin
alreadi
proven
success
increas
surviv
ovarian
cancer
patient
day
show
limit
advers
proprotein
convertas
furin
becom
attract
target
treatment
variou
infecti
noninfecti
diseas
regul
activ
numer
mammalian
bacteri
viral
protein
recent
year
sever
peptid
nonpeptid
inhibitor
develop
block
activ
bacteri
toxin
prevent
matur
viral
protein
suppress
tumor
growth
vitro
although
also
yield
promis
result
mous
model
limit
number
clinic
trial
human
one
major
challeng
redund
furin
relat
proprotein
convertas
also
recognis
polybas
cleavag
site
one
hand
select
inhibit
furin
may
benefici
limit
unwant
side
effect
due
inhibit
pcsk
hand
treatment
diseas
may
requir
simultan
inhibit
sever
pcsk
effici
block
patholog
substrat
convers
advanc
current
approach
better
understand
rel
contribut
individu
pcsk
nonphysiolog
proteolyt
protein
process
urgent
need
therapeut
intervent
need
specif
target
convertas
drive
diseas
progress
current
promis
approach
select
inhibit
silenc
nanobodi
show
littl
effect
even
select
inhibit
individu
pcsk
achiev
system
inhibit
like
detriment
effect
pcsk
requir
activ
hundr
cellular
substrat
thu
local
applic
target
treatment
tumor
topic
treatment
bacteri
viral
infect
may
feasibl
system
therapi
final
abil
tumor
cell
pathogen
evolv
resist
evas
mutat
remain
poorli
investig
exampl
sever
substrat
dengu
viru
prm
harbour
suboptim
furin
target
sequenc
may
optimis
cleavag
site
upon
therapi
enabl
suffici
cleavag
presenc
inhibitor
although
therapeut
applic
furin
inhibitor
may
full
pitfal
certainli
promis
approach
pursu
futur
studi
elucid
role
individu
pcsk
substrat
diseas
progress
better
understand
cellular
pathway
regul
furin
activ
may
uncov
addit
target
therapeut
intervent
author
declar
conflict
interest
eb
ds
perform
literatur
research
eb
draft
figur
ds
wrote
initi
version
manuscript
